Outcome and Prognostic Factors in T4a Oropharyngeal Carcinoma, Including the Role of HPV Infection

Table 3

Oncologic results according to HPV infection and treatment group.

p16	Treatment group; (number of patients)	5-Y-KM-Estimate (%) (Total number of events) (95% CI)
		OS	DSS	LC	RC	DC
*p16-positive	Primary surgical group (5)	*75.0 (2); (32–100)	No events	No events	No events	*75.0 (1); (32–100)
	RCT group (10)	*26.7 (7); (0–56)	*50.0 (5); (19–81)	*90.0 (1); (71–100)	No events	*88.9 (1); (68–100)
p16-negative	Primary surgical group (10)	50.0 (6); (15–85)	*71.4 (2); (38–100)	*62.5 (2); (21–100)	No events	*85.7 (1); (60–100)
	RCT group (65)	19.1 (43); (6–33); 𝑃=0.102	34.0 (30); (15–53); 𝑃=0.113	*86.2 (8); (77–95); 𝑃=0.79	*97.0 (1); (90–100); 𝑃=0.67	*67.5 (5); (35–100); 𝑃=0.81
All (90)		26.9 (58); (15–38)	44.5 (37); (30–59)	79.6 (11); (65–94)	*97.9 (1); (94–100)	*76.8 (8); (58–95)

∗Not enough events or patients for statistical analysis.